Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2

Int J Mol Sci. 2021 Jul 24;22(15):7914. doi: 10.3390/ijms22157914.

Abstract

The outbreak of the coronavirus disease 2019 (COVID-19) began at the end of 2019. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and patients with COVID-19 may exhibit poor clinical outcomes. Some patients with severe COVID-19 experience cytokine release syndrome (CRS) or a cytokine storm-elevated levels of hyperactivated immune cells-and circulating pro-inflammatory cytokines, including interleukin (IL)-1β and IL-18. This severe inflammatory response can lead to organ damage/failure and even death. The inflammasome is an intracellular immune complex that is responsible for the secretion of IL-1β and IL-18 in various human diseases. Recently, there has been a growing number of studies revealing a link between the inflammasome and COVID-19. Therefore, this article summarizes the current literature regarding the inflammasome complex and COVID-19.

Keywords: coronavirus disease 2019; cytokines; inflammasome; severe acute respiratory syndrome coronavirus 2.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity / immunology
  • Animals
  • COVID-19 / complications
  • COVID-19 / immunology*
  • COVID-19 / virology*
  • COVID-19 Drug Treatment
  • Cytokine Release Syndrome / drug therapy
  • Cytokine Release Syndrome / etiology
  • Cytokine Release Syndrome / immunology
  • Humans
  • Inflammasomes / immunology*
  • Inflammasomes / metabolism*
  • Multiple Organ Failure / drug therapy
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / immunology
  • SARS-CoV-2 / immunology*
  • SARS-CoV-2 / metabolism*

Substances

  • Inflammasomes